Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Grows By 94.7%

Jasper Therapeutics, Inc. (NASDAQ:JSPRW) was the recipient of a significant increase in short interest in April. As of April 30th, there was short interest totaling 6,729 shares, an increase of 94.7% from the April 15th total of 3,456 shares. Based on an average trading volume of 14,318 shares, the days-to-cover ratio is currently 0.5 days.

Jasper Therapeutics Price Performance

Shares of JSPRW opened at $0.02 on Tuesday. The firm’s 50 day moving average price is $0.02 and its 200 day moving average price is $0.06. Jasper Therapeutics has a twelve month low of $0.01 and a twelve month high of $0.18.

About Jasper Therapeutics

Jasper Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on developing a new generation of cellular therapeutics for severe diseases. The company’s mission centers on harnessing targeted biological agents and engineered cell platforms to improve outcomes in hematopoietic stem cell transplantation, oncology and gene therapies. By advancing novel approaches to conditioning regimens and cell engineering, Jasper aims to address limitations of existing treatments, including toxicity, graft failure and restricted applicability.

The company’s lead candidate, JSP191, is a humanized monoclonal antibody targeting the CD117 receptor on hematopoietic stem cells.